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Role of iron metabolism in absorption and cellular uptake of aluminum.
The effect of iron status on aluminum (Al) absorption was investigated
in this study in vivo using an animal model and in vitro using an
intestinal mucosal cell line. In the in vivo model rats were rendered iron
overloaded by intraperitoneal injection of iron dextran (5 mg/48 hr) or
iron deficient by phlebotomy (2.5 to 3 ml blood/week). These rats, and
normal controls, were then dosed with Al(OH)3 (40 mg/day) for 30 days.
Urinary excretion of Al was significantly greater in the iron deficient
group than in the other two groups throughout the study period, and
brain Al at the end of the experiment was significantly increased in the
iron depleted group (1.93 g/g) and decreased in the iron overloaded
group (0.73 g/g) compared with controls (1.42 Lg/g). The brain Al
levels in iron overloaded rats were no higher than those in normal rats
that had not been dosed with Al(OH)3 (0.61 rg/g). No significant
differences were found in serum Al levels. In the in vitro experiments
cultures of the rat intestinal cell line RIE I were iron overloaded by
addition of iron nitrilotriacetate (0. 1 mM) or iron depleted with desfer-
rioxamine (5 g/ml) for 20 days prior to pulsing with Al transferrin (0.5
mg/mi) for 24 hours. Uptake of Al was significantly greater in the iron
depleted cells (2.3 ng/fLg cell DNA) than in iron overloaded (0.81 ng) or
untreated (0.83 tg) cells. These studies show that iron depletion
markedly increases absorption and cellular uptake and suggest that
susceptible individuals, such as renal failure patients, run an increased
risk of toxicity if they are iron deficient.
Throughout the past decade a number of studies have dem-
onstrated that aluminum (Al), an element widely distributed in
nature, can have important toxic effects in humans [1—3]. The
first publications drew attention to overloading induced by the
use of dialysis solutions containing high levels of aluminum in
the treatment of chronic renal insufficiency, while subsequent
studies have shown that oral administration can also give rise to
aluminum overload, even when renal function is normal [4—9].
Patients exposed to oral aluminum show a wide individual
variation in the proportion of the administered dose that is
absorbed, as a result of which various factors have been
postulated as regulators of absorption. Aluminum and iron
share certain features in their biochemistry, and we have
previously observed that levels of storage iron may modulate
gastrointestinal absorption of aluminum [10], suggesting that
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both metals may share a common route of absorption. Other
studies have shown that iron and aluminum share the plasma
transport protein, transferrin, and that both iron and aluminum
overload can be treated by the same chelator, desferrioxamine
[10—15]. Finally, we have recently shown in vitro that iron and
aluminum appear to share a common uptake pathway in eryth-
roleukemia cells [16].
It thus seems reasonable to postulate that absorption and
cellular uptake of aluminum is regulated by the same mecha-
nism that controls iron uptake and absorption. The present
study provides experimental in vivo and in vitro evidence in
support of this hypothesis.
Methods
In vivo study
Rats with normal rena/function. Fifty-two male Wistar rats,
body weight 250 to 300 g, were divided into three experimental
groups. Group 1 (N = 19) was comprised of rats with iron
overload induced by intraperitoneal administration of 5 mg of
iron dextran (Imferon®) every 48 hours. Group 2 (N =20) was
untreated rats with normal iron stores. Group 3 (N = 13) rats
had depleted iron stores induced by weekly removal of 2.5 to 3
ml of blood. The induction of iron overload and iron depletion
was begun one month before day 0 and the relevant treatment
was maintained throughout the 30 days of study. All animals
received a diet containing 17% protein, 3% lipids, 58.7%
carbohydrate, 4.3% cellulose and 5% minerals. The iron con-
tent of the diet for Groups 1 and 2 was 254 tg/g and the
aluminum content 258 sg/g, while for Group 3 a diet containing
less iron (166 ig/g) and 279 g/g of aluminum was used.
One month after commencing the regimens of iron overload
or depletion 49 rats remained alive: Group 1 N = 16, Group 2
N = 20, Group 3 N = 13. All animals received a daily dose of
40mg of Al(OH)1, (13.85 mg of Al element) administered via the
drinking water, for 30 days and each day the amount of Al(OH)3
consumed was measured. During this time animals were kept in
individual cages and were transferred periodically to metabolic
cages to obtain urine samples. The microhematocrit, and blood
and urinary aluminum levels were determined at days 0, 15 and
30. In Group 3, seven rats died during the last 10 days of the
experiment and thus seven animals completed the study. The
concentration of aluminum in the brain was determined in five
animals per group at the end of the experiment (day 30).
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Rats with chronic renal failure. Twenty male Wistar rats,
body weight 250 to 300 g, were rendered uremic by performing
unilateral nephrectomy and contralateral bipolar nephrectomy,
as we have described elsewhere [171. This caused an increase in
serum creatinine (0.56 0.17 to 1.1 0.5 mg/dl), an increase in
BUN (blood urea nitrogen) (15.8 2.6 to 44.5 19.7 mg/dl) and
a fall in creatinine clearance (2.1 1.3 to 0.99 0.4 ml!m).
The animals were divided in three groups: Group 1 (N = 5),
rats with iron overload; Group 2 (N = 4), rats with normal iron
stores, and Group 3 (N = 11), rats with depleted iron stores.
The iron overload and depletion was induced as in animals with
normal renal function, commencing a fortnight after the surgery
and maintained for four weeks. At the end of this period four
animals died in Group 3 and there were no changes in the other
two groups. All three groups received a standard diet as was
used in Groups 1 and 2 with normal renal function.
Four weeks after commencing the regimes of iron overload or
depletion the rats were transferred to metabolic cages. During
the next 24 hours the animals were fasted, receiving only
deionized water ad libitum, and we measured 24-hour urinary
aluminum excretion. After this 24 hour period hematocrit and
serum aluminum were measured. An acute aluminum absorp-
tion test was then performed by administering 24.4 mg/100 g
body wt of AlCl3 (5 mg of element Al) by a gastroesophageal
catheter followed by 1 ml of deionized water as lavage.
Serum Al levels were measured at 3, 6 and 24 hours after the
Al load and urinary Al excretion during 48 hours. We also
calculated the absorption area under the curve.
Common methodology. All samples were collected in poly-
styrene tubes that had been washed in nitric acid, and were
stored at —20°C. Aluminum determination was carried out by
atomic absorption spectroscopy in a Perkin-Elmer 3030 spec-
trometer with a HGA 600 graphite oven [181 and background
correction (Zeeman effect). Aluminum in tissues was deter-
mined after dispersion with a teflon homogenizer followed by
treatment with concentrated nitric acid for three hours at 90°C
and then for a further three hours at 120°C [81. Aluminum
concentrations are expressed as ig/1iter in serum, g/24 hr in
urine and p.g/g of tissue.
In vitro study
The in vitro study was carried out using the rat intestinal
epithelial cell line RIE1 [191. Cells were maintained in RPMI
1640 medium (Flow Laboratories, Rickmansworth, UK) sup-
plemented with 10% fetal calf serum (Flow Labs) and 100 sg/ml
streptomycin + 100 U/mI penicillin (Flow Labs). Confluent
cultures were subcultured at a 1:10 ratio using 0.05% trypsin +
0.02% EDTA. Aluminum contamination of reagents and appa-
ratus was checked as described elsewhere [161. The aluminum
content of the complete tissue culture medium was 1 to 2 nglml
[161.
To relate aluminum uptake to the degree of iron loading, cells
were cultured in 12-well tissue culture plates (Flow Labs) and
pretreated as follows: Group 1, cells were iron overloaded by
preincubation for 20 days with 0.1 m iron nitrilotriacetate,
prepared as described by Graham and Bates [20]; Group 2,
normal cells, incubated in standard medium; Group 3, cells
were iron depleted by preincubation with 5 g/ml desferriox-
amine (DFO; Desferapa, Ciba-Geigy, Horsham, UK) for 20
days, the DFO being replenished every 48 hours due to its
instability in aqueous solution. The preincubation of the cells
with iron nitrilotriacetate and desferrioxamine has been dem-
onstrated to be an effective model to obtain iron loaded or iron
depleted intestinal cells [211. To determine aluminum uptake,
the cells were first washed three times with warm RPMI 1640
and then incubated for 24 hours in serum-free RPMI 1640
containing 500 jig/ml aluminum transferrin complex (100%
saturated), prepared 24 hours previously from AIC13 and human
apotransferrin (Hoechst, Hounslow, UK) using a method de-
scribed elsewhere [16]. The cells were then washed three times
in RPMI 1640 at 4°C, dissolved in I ml of 2% sodium dodecyl
sulphate (SDS) and freeze-thawed. The liquid was then re-
moved from the wells, which were washed out with a further 1
ml of SDS, and the combined fractions used for determination
of aluminum as described above. Total cell DNA in the lysates
was determined by a microfluorimetric method [22].
Statistics
Results are expressed as ng aluminum incorporated per jg of
cell DNA. Statistical evaluation was carried out using Student's
t-test and the Snedecor F test.
Results
In vivo study
Normal renalfunction. As can be seen in Table 1, the average
microhematocrits of the iron depleted group of rats over the
Table 1. Microhematocrit values of normal, iron overloaded and iron depleted rats during a 30-day oral administration of Al(OH)3
(40 mg/day)
Group
Microhematocrit (%) at days Average of all
measurements0 (1) 15 (2) 30 (3)
Fe overload 53,1 4.2
12
53.0 2.1
12
54.3 2.5
16
53.8 2.8
50
Normal 52.8 1.4
15
47.7 8.7
17
51.5 2.1
18
50.2 5.3
70
Fe depletion 45.8 6.0
9
43.5 2.6
12
33.0 4.8
7
41.6 6.7
28
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Table 2. Serum aluminum concentration in normal iron overloaded
and iron depleted rats during a 30-day oral administration of Al(OH)3
(40 mg/day)
Days
0 15 30
Fe overload 40.6
7
14.9 31.3
7
16.1 32.4 20.1
11
Normal 56.0
11
26.4 36.8
9
34.0 39.6 29.3
14
Fe depletion 24.9
11
9.9 42.6
9
19.7 35.5 18.8
7
Data are presented as means SD
Fig. 1. Urinary aluminum (Al) concentrations (g/24 hr) in rats dosed
orally with 40 mg/day of Al(OH)3 before (day 0), during (day 15) and at
the end (day 30) of the study. Symbols are: (U) Fe overload; ()
normal; (E) Fe depletion. Data are means SD.
Fig. 2. Brain aluminum (Al) levels (jsg/g) in normal, iron overloaded
and iron deficient rats dosed for 30 days with Al(OH)3 (40 mg/day), and
in normal rats without Al(OH)3. Data are mean SD.
30-day experimental period were significantly lower, and those
of the iron overloaded group significantly higher than the
controls. Significant differences between the groups were also
observed at each individual time interval.
During oral administration of Al(OH)5 over the 30 day period,
urinary aluminum progressively increased (Fig. 1), and was
most marked in the iron depleted group. Even at day 0, when
the animals had received only the aluminum present in the diet,
urinary aluminum was significantly greater in the iron depleted
group than in the other two groups. This difference increased
markedly during the 30 days of overload with Al(OH)1. Levels
of aluminum in the brain showed a similar tendency (Fig. 2),
that is, the highest concentration was observed in the iron
deficient animals and the lowest in the iron overloaded group.
The brain aluminum levels in the latter group were only
marginally higher than those observed in normal control rats
not receiving Al(OH)1. In contrast, there were no significant
differences in serum aluminum levels between the groups at any
time during the study (Table 2).
Chronic renal failure. When the AId1 absorption test was
performed, the microhesnatocrit of the iron depleted group was
Table 3. Microhematocrit values of iron overloaded, normal and iron
depleted rats at the beginning of the AId1 absorption test
Fe overload Normal Fe Fe depletion
56.8 4.9 52.2 3.2 35.1 2.la(N=5) (N=4) (N=7)
Data are presented as means SD
a P < 0.01
165
150
135
120
105
90
75
ci 60
45
30
15
0
Fig. 3. Serum aluminum increments and absorption area under the
curve in rats with chronic renal failure receivingAlCl3. Symbols are:
(LI) Fe overloaded; (•) normal; (U) Fe depleted. Group 1: 458 185
j.g/liter (x hr), Group 2: 655 190 pg/liter (x hr), Group 3: 1388 951
pg/liter (x hr). *D < 0.05.
significantly lower than in the iron overloaded rats (35.1 2.1
vs. 56.8 4.9, P < 0.01; Table 3).
The serum Al observed after Aid!3 administration was signif-
icantly higher at three and six hours than in normal and Fe
overloaded rats (P < 0.05; Fig. 3). In addition, the absorption
area under the curve also correlated inversely with the degree
of Fe loading (Fig. 3).
Throughout the study Fe depleted rats showed the higher
urinary aluminum excretion. In all groups values rose during
the first 24 hours, nearly returning to pre-test values 48 hours
after the test (Fig. 4).
In vitro study. RIE1 cells depleted of iron by preincubation
with desferrioxamine took up significantly more aluminum
when exposed to aluminum transferrin than did normal or iron
overloaded cells (Fig. 5; P < 0.01). There was no difference
between the normal and iron overloaded cultures.
655 190
458±185
Basal 3 hours 6 hours 24 hours
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Fig. 4. Urinary aluminum levels after
chronic renal failure,
Discussion
Although aluminum has no known natural biological function
it is toxic in patients with chronic renal insufficency, and has
recently been shown to have potential toxicity in patients with
normal renal function [71. Intestinal absorption of aluminum
depends upon the luminal concentration of the element, the
bioavailability and the degree of stimulation or inhibition of the
physiological mechanisms involved in absorption. It is not
known whether specific mechanisms exist which stimulate or
decrease aluminum absorption, although recent studies have
suggested that it may be partially regulated by a negative
feedback mechanism [23]. Despite the fact that various studies
have confirmed that absorption of aluminum depends upon its
solubility and various other factors [24j, they have had little
impact in reducing oral exposure to aluminum, as the large
number of factors involved and individual variations have made
it impossible to modify specific treatments, other than that of
reducing the use of phosphate binders containing aluminum.
Iron, on the other hand, performs various well-established
biological functions, and it is known that uptake from the
digestive tract is inversely related to body iron stores. The
actual mechanisms involved are still unclear, although absorp-
tion correlates with plasma iron utilization and uptake from the
intestinal mucosa [251; both of these are increased in iron
deficiency.
In this study we used different models aiming not to establish
a comparison, but to investigate the effect of iron status on
aluminum absorption and aluminum uptake. In the in vivo
phase we first used Al(OH)5 for a month, a less absorbable but
currently used form of aluminum without altering the renal
function of the rats. We then designed the second phase using
A1CI3, a more soluble and absorbable form of aluminum, and
performed an acute absorption test in animals with chronic
renal failure.
The results show that iron status may be a factor which could
explain some of the variations in aluminum absorption reported
in previous studies. Due to their chemical similarities, alumi-
num and iron may share common metabolic routes and each
may regulate the uptake of the other. Both are bound by
transferrin, which even in conditions of hyperabsorption of iron
still possesses sufficient binding capacity to transport alumi-
num. While early studies showed that only 65 to 75% of
Fig. 5. Intracellular concentrations of aluminum (Al) (ng Al/pg DNA)
in RIEI cells pre-cultured under normal conditions or in the presence of
0.1 smolIml Fe nitrilotriacetate (Fe overload) or 5 gIml desferrioxam-
inc (DFO). Data are mean so.
aluminum was transferrin-bound, more recent studies have put
the figure at greater than 90% [12, 131. In iron deficiency,
absorption and cellular uptake are increased, and if aluminum is
also available it seems likely that its uptake also will increase.
On the other hand, iron sufficiency reduces iron absorption and
would thus offer a certain degree of protection against alumi-
num absorption. This concept is supported by recent studies
demonstrating that aluminum intoxication reduces absorption
[21, 261 and cellular uptake [161 of iron.
Figure 1 shows that urinary aluminum excretion over 24
hours, which is considered to be the most reliable method of
determining aluminum absorption in the presence of normal
renal function, was significantly increased in animals rendered
iron deficient by phlebotomy. This hyperabsorption of alumi-
num is also supported by brain aluminum levels assayed at the
end of the experiment, and also by the serum and urinary
results obtained in those rats with chronic renal failure (Figs. 3
and 4) which show that there is a higher bioavailability of
aluminum in iron deficiency. This interaction and competition
in vivo between aluminum and iron absorption requires further
investigation, and is unlikely to be completely understood until
the mechanisms regulating iron absorption are known. How-
ever, there seem to be common intracellular regulatory mech-
anisms for Fe and Al [161, so the increased transfer of iron
across the gut during iron deficiency is likely to be parallelled by
an increase in Al transfer.
These in vivo results compare well both qualitatively and
quantitatively with the in vitro study using the intestinal cell
line, which showed nearly a threefold increase in aluminum
uptake in the iron depleted cells compared with the other
groups. In both the in vivo and the in vitro experiments the
most notable differences were observed between the iron defi-
cient group and the other two groups. Differences between the
controls and iron overload group were in both cases less
pronounced. This is not surprising as it is known that iron
absorption is not much lower in iron overload than under
normal conditions, since absorption is near to minimal even in
normals [251.
As has previously been demonstrated by us [7] and others [8,
22
Basal 24 hours 48 hours
AIC!3 loading in rats with r'iiTt
Fe qverload NQrnI Fc deplfliQn
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27] in normal renal function and in long-term studies, serum
aluminum levels have limited usefulness in determining the
degree of clinical aluminum overload, and should be accompa-
nied by urinary or tissue aluminum determinations. The present
results reinforce this fact, as despite the marked differences in
urinary and brain aluminum levels in the different groups of rats
no significant differences in serum aluminum levels were ob-
served.
While some aspects of this study will require further confir-
mation, the present work provides evidence for a common
route of gastrointestinal absorption of aluminum and iron, and
suggests that in iron deficiency, aluminum absorption is in-
creased, and with it the risk of toxicity. On the other hand, iron
sufficiency would offer a certain degree of protection against
aluminum absorption.
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